Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Prat

Showing results (201-210 of 205) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 205 results.
British Journal of Cancer|August 8, 2014
Predicting response and survival in chemotherapy-treated triple-negative breast cancerA Prat, A Lluch, J Albanell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2024
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapyM Martín, S R Stecklein, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2023
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trialK Jhaveri, L D Eli, H Wildiers, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world studyO Martínez-Sáez, M Tapia, M Marín-Aguilera, et al.
BMC Medical Research Methodology|May 31, 2022
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosisM Lefort, S Sharmin, J B Andersen, et al.
Pageof 21

Showing results (201-210 of 205) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 205 results.
British Journal of Cancer|August 8, 2014
Predicting response and survival in chemotherapy-treated triple-negative breast cancerA Prat, A Lluch, J Albanell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2024
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapyM Martín, S R Stecklein, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2023
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trialK Jhaveri, L D Eli, H Wildiers, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world studyO Martínez-Sáez, M Tapia, M Marín-Aguilera, et al.
BMC Medical Research Methodology|May 31, 2022
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosisM Lefort, S Sharmin, J B Andersen, et al.
Pageof 21